Originally published as JCO Early Release 10.1200/JCO.2005.09.131 on May 2 2005
Journal of Clinical Oncology, Vol 23, No 18 (June 20), 2005: pp. 4117-4126
© 2005 American Society of Clinical Oncology.
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
P. Feugier,
A. Van Hoof,
C. Sebban,
P. Solal-Celigny,
R. Bouabdallah,
C. Fermé,
B. Christian,
E. Lepage,
H. Tilly,
F. Morschhauser,
P. Gaulard,
G. Salles,
A. Bosly,
C. Gisselbrecht,
F. Reyes,
B. Coiffier
From the Centre Hospitalier Universitaire (CHU) de Brabois, Vandoeuvre les Nancy; Centre Leon Bérard, Lyon; Centre Jean Bernard, Le Mans; Institut Paoli Calmette, Marseille; Institut Gustave Roussy, Villejuif; Hôpital Bon Secours, Metz; CHU Henri Mondor, Créteil; Centre Becquerel, Rouen; CHU de Lille, Lille; Hospices Civils de Lyon, Pierre-Bénite; Hôpital Saint-Louis, Paris, France; Université Catholique de Louvain, Yvoir; and Academisch Ziekenhuis Sint-Jan, Bruges, Belgium
Address reprint requests to Pierre Feugier, MD, Hematology Department, CHU de Brabois, 54500 Vandoeuvre les Nancy, France; e-mail: p.feugier{at}chu-nancy.fr
PURPOSE: To analyze the long-term outcome of patients included in the Lymphome Non Hodgkinien study 98-5 (LNH98-5) comparing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) in elderly patients with diffuse large B-cell lymphoma.
PATIENTS AND METHODS: LNH98-5 was a randomized study that included 399 previously untreated patients, age 60 to 80 years, with diffuse large B-cell lymphoma. Patients received eight cycles of classical CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, and prednisone 40 mg/m2 for 5 days) every 3 weeks. In R-CHOP, rituximab 375 mg/m2 was administered the same day as CHOP. Survivals were analyzed using the intent-to-treat principle.
RESULTS: Median follow-up is 5 years at present. Event-free survival, progression-free survival, disease-free survival, and overall survival remain statistically significant in favor of the combination of R-CHOP (P = .00002, P < .00001, P < .00031, and P < .0073, respectively, in the log-rank test). Patients with low-risk or high-risk lymphoma according to the age-adjusted International Prognostic Index have longer survivals if treated with the combination. No long-term toxicity appeared to be associated with the R-CHOP combination.
CONCLUSION: Using the combination of R-CHOP leads to significant improvement of the outcome of elderly patients with diffuse large B-cell lymphoma, with significant survival benefit maintained during a 5-year follow-up. This combination should become the standard for treating these patients.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. A. White, A. P. DeHaan, J. M. Wilson, M. H. Zakem, and T. J. Maatman
Synchronous Advanced Pure Seminoma and Diffuse Large B-Cell Lymphoma: A Case of Multiple Oncologic Dilemmas
J. Clin. Oncol.,
November 10, 2009;
27(32):
e181 - e183.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Gundrum, M. A. Mathiason, D. B. Moore, and R. S. Go
Primary Testicular Diffuse Large B-Cell Lymphoma: A Population-Based Study on the Incidence, Natural History, and Survival Comparison With Primary Nodal Counterpart Before and After the Introduction of Rituximab
J. Clin. Oncol.,
November 1, 2009;
27(31):
5227 - 5232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Villa, J. M. Connors, T. N. Shenkier, R. D. Gascoyne, L. H. Sehn, and K. J. Savage
Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy
Ann. Onc.,
October 27, 2009;
(2009)
mdp432v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gisselbrecht, J. Vose, A. Nademanee, A. M. Gianni, and A. Nagler
Radioimmunotherapy for Stem Cell Transplantation in Non-Hodgkin's Lymphoma: In Pursuit of a Complete Response
Oncologist,
October 1, 2009;
14(suppl_2):
41 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Al Zahrani, N. Ibrahim, and A. Al Eid
Rapid Infusion Rituximab Changing Practice for Patient Care
Journal of Oncology Pharmacy Practice,
September 1, 2009;
15(3):
183 - 186.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. R. Carson, A. M. Evens, E. A. Richey, T. M. Habermann, D. Focosi, J. F. Seymour, J. Laubach, S. D. Bawn, L. I. Gordon, J. N. Winter, et al.
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Blood,
May 14, 2009;
113(20):
4834 - 4840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson and M. J. Rummel
Bendamustine: Rebirth of an Old Drug
J. Clin. Oncol.,
March 20, 2009;
27(9):
1492 - 1501.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. McLaughlin
A Look in the Mirror
J. Clin. Oncol.,
March 10, 2009;
27(8):
1158 - 1159.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Grange, E. Maubec, M. Bagot, M. Beylot-Barry, P. Joly, S. Dalle, E. Delaporte, O. Dereure, H. Bachelez, B. Vergier, et al.
Treatment of Cutaneous B-Cell Lymphoma, Leg Type, With Age-Adapted Combinations of Chemotherapies and Rituximab
Arch Dermatol,
March 1, 2009;
145(3):
329 - 330.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dupuis, E. Itti, A. Rahmouni, F. Hemery, C. Gisselbrecht, C. Lin, C. Copie-Bergman, K. Belhadj, T. El Gnaoui, I. Gaillard, et al.
Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria
Ann. Onc.,
March 1, 2009;
20(3):
503 - 507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Y. Zhao, A. Auerbach, A. M. D'Costa, A. P. Rapoport, A. M. Burger, E. A. Sausville, S. A. Stass, F. Jiang, A. M. Sands, N. Aguilera, et al.
Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy
Clin. Cancer Res.,
March 1, 2009;
15(5):
1708 - 1720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. V. Lee, C. A. Green, O. G. Negrea, S. Dodson, S. K. Farrell, J. E. Hewitt, T. Jago, C. E. Ramsey, T. Cato, E. Crawford, et al.
B-Cell Lymphoma With Intermediate- to High-Grade Features and Different Immunophenotypic Profiles Involving Separate Anatomic Sites With a Good Response to R-CHOP
Lab Med,
February 1, 2009;
40(2):
79 - 86.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Jahnke, L. L. Muldoon, C. G. Varallyay, S. J. Lewin, R. D. Brown, D. F. Kraemer, C. Soussain, and E. A. Neuwelt
Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma
Neuro-oncol,
January 1, 2009;
11(5):
503 - 513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Psyrri, S. Papageorgiou, and T. Economopoulos
Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management
Ann. Onc.,
December 1, 2008;
19(12):
1992 - 1999.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. H. Wiernik, I. S. Lossos, J. M. Tuscano, G. Justice, J. M. Vose, C. E. Cole, W. Lam, K. McBride, K. Wride, D. Pietronigro, et al.
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
October 20, 2008;
26(30):
4952 - 4957.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Fu, D. D. Weisenburger, W. W.L. Choi, K. D. Perry, L. M. Smith, X. Shi, C. P. Hans, T. C. Greiner, P. J. Bierman, R. G. Bociek, et al.
Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell-Like and Non-Germinal Center B-Cell-Like Subtypes of Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
October 1, 2008;
26(28):
4587 - 4594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Habermann, S. S. Wang, M. J. Maurer, L. M. Morton, C. F. Lynch, S. M. Ansell, P. Hartge, R. K. Severson, N. Rothman, S. Davis, et al.
Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era
Blood,
October 1, 2008;
112(7):
2694 - 2702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Mead, S. L. Barrans, W. Qian, J. Walewski, J. A. Radford, M. Wolf, S. M. Clawson, S. P. Stenning, C. L. Yule, A. S. Jack, et al.
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
Blood,
September 15, 2008;
112(6):
2248 - 2260.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson and J. P. Leonard
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
N. Engl. J. Med.,
August 7, 2008;
359(6):
613 - 626.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Wilson, K. Dunleavy, S. Pittaluga, U. Hegde, N. Grant, S. M. Steinberg, M. Raffeld, M. Gutierrez, B. A. Chabner, L. Staudt, et al.
Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers
J. Clin. Oncol.,
June 1, 2008;
26(16):
2717 - 2724.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Crump, B. Coiffier, E. D. Jacobsen, L. Sun, J. L. Ricker, H. Xie, S. R. Frankel, S. S. Randolph, and B. D. Cheson
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
Ann. Onc.,
May 1, 2008;
19(5):
964 - 969.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Jaeger, F. Bauer, R. Brezinschek, C. Beham-Schmid, C. Mannhalter, and P. Neumeister
Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine
Ann. Onc.,
May 1, 2008;
19(5):
1025 - 1026.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Zinzani, M. Tani, S. Fanti, V. Stefoni, G. Musuraca, P. Castellucci, E. Marchi, M. Farsad, M. Fina, C. Pellegrini, et al.
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients
Ann. Onc.,
April 1, 2008;
19(4):
769 - 773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Vellenga, W. L. J. van Putten, M. B. van 't Veer, J. M. Zijlstra, W. E. Fibbe, M. H. J. van Oers, L. F. Verdonck, P. W. Wijermans, G. W. van Imhoff, P. J. Lugtenburg, et al.
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial
Blood,
January 15, 2008;
111(2):
537 - 543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Krishnan, A. Nademanee, H. C. Fung, A. A. Raubitschek, A. Molina, D. Yamauchi, R. Rodriguez, R. T. Spielberger, P. Falk, J. M. Palmer, et al.
Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
January 1, 2008;
26(1):
90 - 95.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. G. M. Cillessen, J. C. Reed, K. Welsh, C. Pinilla, R. Houghten, E. Hooijberg, J. Deurhof, K. C. M. Castricum, P. Kortman, C. J. Hess, et al.
Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells
Blood,
January 1, 2008;
111(1):
369 - 375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Zhao, R. Lapalombella, T. Joshi, C. Cheney, A. Gowda, M. S. Hayden-Ledbetter, P. R. Baum, T. S. Lin, D. Jarjoura, A. Lehman, et al.
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical
Blood,
October 1, 2007;
110(7):
2569 - 2577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Martin, R. R. Furman, M. Coleman, and J. P. Leonard
Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma
Clin. Cancer Res.,
September 15, 2007;
13(18):
5636s - 5642s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Fillet and C. Bonnet
In Reply
J. Clin. Oncol.,
July 1, 2007;
25(19):
2857 - 2858.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Mitrovic, I. Aurer, I. Radman, R. Ajdukovic, J. Sertic, and B. Labar
FC{gamma}RIIIA and FC{gamma}RIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma
Haematologica,
July 1, 2007;
92(7):
998 - 999.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O. Armitage
How I treat patients with diffuse large B-cell lymphoma
Blood,
July 1, 2007;
110(1):
29 - 36.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Morschhauser, T. Illidge, D. Huglo, G. Martinelli, G. Paganelli, P. L. Zinzani, S. Rule, A. M. Liberati, N. Milpied, G. Hess, et al.
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation
Blood,
July 1, 2007;
110(1):
54 - 58.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Lichtman, L. Balducci, and M. Aapro
Geriatric Oncology: A Field Coming of Age
J. Clin. Oncol.,
May 10, 2007;
25(14):
1821 - 1823.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Lichtman, H. Wildiers, E. Chatelut, C. Steer, D. Budman, V. A. Morrison, B. Tranchand, I. Shapira, and M. Aapro
International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients--An Analysis of the Medical Literature
J. Clin. Oncol.,
May 10, 2007;
25(14):
1832 - 1843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Terret, G. B. Zulian, A. Naiem, and G. Albrand
Multidisciplinary Approach to the Geriatric Oncology Patient
J. Clin. Oncol.,
May 10, 2007;
25(14):
1876 - 1881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Thieblemont and B. Coiffier
Lymphoma in Older Patients
J. Clin. Oncol.,
May 10, 2007;
25(14):
1916 - 1923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Schulz, J. F. Bohlius, S. Trelle, N. Skoetz, M. Reiser, T. Kober, G. Schwarzer, M. Herold, M. Dreyling, M. Hallek, et al.
Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis
J Natl Cancer Inst,
May 2, 2007;
99(9):
706 - 714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H Veelken, S Vik Dannheim, J Schulte Moenting, U. Martens, J Finke, and A Schmitt-Graeff
Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy
Ann. Onc.,
May 1, 2007;
18(5):
931 - 939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bonnet, G. Fillet, N. Mounier, G. Ganem, T. J. Molina, C. Thieblemont, C. Ferme, B. Quesnel, C. Martin, C. Gisselbrecht, et al.
CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
J. Clin. Oncol.,
March 1, 2007;
25(7):
787 - 792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Sehn, B. Berry, M. Chhanabhai, C. Fitzgerald, K. Gill, P. Hoskins, R. Klasa, K. J. Savage, T. Shenkier, J. Sutherland, et al.
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Blood,
March 1, 2007;
109(5):
1857 - 1861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Dunleavy, R. E. Davis, O. Landgren, L. M. Staudt, and W. H. Wilson
BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?
Blood,
January 15, 2007;
109(2):
843 - 844.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Arnold, F. Dentali, M. A. Crowther, R. M. Meyer, R. J. Cook, C. Sigouin, G. A. Fraser, W. Lim, and J. G. Kelton
Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura
Ann Intern Med,
January 2, 2007;
146(1):
25 - 33.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Habermann
Antibody Therapy in Aggressive Lymphomas
Hematology,
January 1, 2007;
2007(1):
257 - 264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Forstpointner, M. Unterhalt, M. Dreyling, H.-P. Bock, R. Repp, H. Wandt, C. Pott, J. F. Seymour, B. Metzner, A. Hanel, et al.
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Blood,
December 15, 2006;
108(13):
4003 - 4008.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Kim, H. D. Jung, J. G. Kim, J.-J. Lee, D.-H. Yang, Y. H. Park, Y. R. Do, H. J. Shin, M. K. Kim, M. S. Hyun, et al.
FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma
Blood,
October 15, 2006;
108(8):
2720 - 2725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. G. Brunstein, D. J. Weisdorf, T. DeFor, J. N. Barker, J. Tolar, J.-A. H. van Burik, and J. E. Wagner
Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation
Blood,
October 15, 2006;
108(8):
2874 - 2880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Betticher, G Martinelli, J. Radford, M Kaufmann, M. Dyer, U Kaiser, W. Aulitzky, J Beck, A von Rohr, T Kovascovics, et al.
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL)
Ann. Onc.,
October 1, 2006;
17(10):
1546 - 1552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Habermann, E. A. Weller, V. A. Morrison, R. D. Gascoyne, P. A. Cassileth, J. B. Cohn, S. R. Dakhil, B. Woda, R. I. Fisher, B. A. Peterson, et al.
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
July 1, 2006;
24(19):
3121 - 3127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Stewart, N. Bahlis, K. Valentine, A. Balogh, L. Savoie, D. G. Morris, A. Jones, C. Brown, and J. A. Russell
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma
Blood,
June 15, 2006;
107(12):
4623 - 4627.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Provencio, S. Cerdeira, F. Bonilla, A. Sanchez, and P. Espana
Rapid-infusion rituximab in lymphoma treatment
Ann. Onc.,
June 1, 2006;
17(6):
1027 - 1028.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-M. Tsimberidou, S. O'Brien, I. Khouri, F. J. Giles, H. M. Kantarjian, R. Champlin, S. Wen, K.-A. Do, S. C. Smith, S. Lerner, et al.
Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation
J. Clin. Oncol.,
May 20, 2006;
24(15):
2343 - 2351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Zuckerman, R. Seliem, and E. Hochberg
Intravascular Lymphoma: The Oncologist's "Great Imitator".
Oncologist,
May 1, 2006;
11(5):
496 - 502.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kober, H. Hulsewede, J. Bohlius, and A. Engert
Fourth biannual report of the Cochrane Haematological Malignancies Group.
J Natl Cancer Inst,
April 19, 2006;
98(8):
E1 - E1.
[Full Text]
|
|
|
|
|
|
|
J. S. Abramson
T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management.
Oncologist,
April 1, 2006;
11(4):
384 - 392.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Dunleavy, W. H. Wilson, and L. D. Kaplan
The case for rituximab in AIDS-related lymphoma.
Blood,
April 1, 2006;
107(7):
3014 - 3015.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Sehn
Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma
Hematology,
January 1, 2006;
2006(1):
295 - 302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Coiffier
State-of-the-Art Therapeutics: Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6387 - 6393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Abramson and M. A. Shipp
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach
Blood,
August 15, 2005;
106(4):
1164 - 1174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Ansell and J. Armitage
Non-Hodgkin Lymphoma: Diagnosis and Treatment
Mayo Clin. Proc.,
August 1, 2005;
80(8):
1087 - 1097.
[Abstract]
[PDF]
|
|
|
|
